Biophysical radiosensitization.
Experimental studies on normal and tumor-bearing rats revealed that chronic treatment with hydroquinone (5 mg/kg/day) inhibited catalase activity in liver, spleen, blood, and H 18R tumor. 3H-hydroquinone (1.5 microCi/g body weight) showed tumor specificity, with maximum radioactivity in the tumor at 1 h after administration. The biological half-time of 3H-hydroquinone in the tumor was 2 h, but there seems to exist a longer component, since 24 h after administration, some 30% of the maximum radioactivity could be detected in the tumor. Hydroquinone treatment produces a specific inhibition of catalase in the tumor and a higher degree of oxygenation at this level. These findings support the assumption that the mechanism of action of hydroquinone as an anticancer agent is achieved mainly via peroxide production. The oxygenation of the hypoxic tumoral tissue is done at non-toxic levels of hydroquinone, through a natural and specific biophysical pathway, recommending hydroquinone for combined anticancer treatment (radiotherapy and chemotherapy).
D000818:Animals; D002374:Catalase / Q000037:antagonists & inhibitors; D006873:Hydroquinones / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009374:Neoplasms, Experimental / Q000378:metabolism; D011485:Protein Binding; D011838:Radiation-Sensitizing Agents; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
D006873:Hydroquinones; D011838:Radiation-Sensitizing Agents; D014316:Tritium; D002374:Catalase; C031927:hydroquinone